Individuals with myasthenia gravis (MG) lived 15 to 19 years longer than those with multiple sclerosis (MS), across 4 ...

Hepatitis B elimination requires expanded vaccination, screening, treatment, and education, Helen Nde, MPH, said. Nde framed ...

MINT randomized 238 patients to inebilizumab 300 mg IV vs placebo with a protocol-driven taper to prednisone ≤5 mg/day and ...

FDA approves brepocitinib, the first oral, targeted therapy for adult dermatomyositis, backed by phase 3 VALOR data. For the ...

Transplant weight-loss access, a new dermatomyositis drug, mifepristone safety views, and racial gaps in cataract surgery and ...

Children and young adults who were unvaccinated and infected with COVID-19 were at an increased risk of developing ...

Tirzepatide is now approved to lower cardiovascular death, heart attack, or stroke risk in adults with type 2 diabetes.

FDA has approved rusfertide, a groundbreaking therapy that promises to spare patients with polycythemia vera (PV) repeated phlebotomies, the agency and officials from Takeda and P ...

Population Health, Equity & Outcomes is a quarterly publication dedicated to providing a platform for the exchange of research, policy analysis, and insights that aim to improve health outcomes and ...

T-cell therapy has transformed outcomes in several blood cancers, but its success is far from uniform. According to Kerry ...

China survey reveals what R/R mantle cell lymphoma patients and doctors value after BTK failure—overall survival tops trade-offs despite CRS risk. Despite advances in recent years, treatment choices ...

The findings reinforce monitoring and managing thrombotic risk across the PV population rather than focusing on traditionally ...